

WEDI NOS

The logo consists of the text 'WEDI' stacked above 'NOS' in a bold, black, sans-serif font. A red ECG line starts at the bottom left, crosses the 'W' and 'E' of 'WEDI', and continues horizontally across the 'D' and 'I'. A white silhouette of a person stands inside the 'I' of 'WEDI'. A grey shadow is cast to the right of the person silhouette.

Collecting • Testing • Informing



1st Sept to 30th Sept 2022

- 511 samples analysed (20 CJS, 72 NTE, 419 community submissions)
 - 78 substances identified
 - Samples received from across UK
 - 23 services
 - Including: Health, Substance Misuse Services, Housing and Homelessness, Night Time Economy, Criminal Justice Services and Welsh Prisons
 - Alongside samples submitted anonymously by individuals

Sex / age profile of sample providers



- Sex (where listed n=401 of 419 community samples)
 - Male: 73% (n=293)
 - Female: 27% (n=108)
- Age
 - Range: 15 to 80yrs
 - Male age range: 15 to 80yrs
 - Female age range: 16 to 56yrs

Community Submissions

(excl. CJS, NTE and ED)

No.	Community purchase intent
1	Diazepam
2	MDMA
3	Cocaine
4	Unknown
5	Alprazolam
6	Ketamine
7	THC
8	Amphetamine
9	Zopiclone
10	LSD

Community Submissions

(excl. CJS, NTE and ED)




No.	Community purchase intent	Community post analysis
1	Diazepam	MDMA
2	MDMA	Bromazolam
3	Cocaine	Cocaine
4	Unknown	Diazepam
5	Alprazolam	Ketamine
6	Ketamine	Caffeine
7	THC	No Active Component Identified
8	Amphetamine	Etizolam
9	Zopiclone	Paracetamol
10	LSD	Amphetamine

Benzodiazepines

- 13 Benzodiazepines identified
 - Diazepam (102 purchase intent / 40 identifications)
 - Alprazolam (25 purchase intent / 10 identifications)
 - Etizolam (3 purchase intent / 21 identifications)
 - Bromazolam (1 purchase intent / 52 identifications)
 - Flubromazolam (0 purchase intent / 10 identifications)
 - Lorazepam
 - Clonazepam
 - Clobromazolam
 - Deschloroetizolam
 - Flubromazepam
 - Methylclonazepam
 - Nitrazepam
 - Temazepam

**Purchase intent and
identifications <5**

Contents of samples submitted as Diazepam: Sep 2022



Diazepam sample providers:

Age range: 21 to 65yrs
Median: 40

MDMA submissions



Pills (n=27)

- Age range: 19 to 53yrs
 - Median age: 30yrs
 - 89% male / 11% female
- 93 per cent (n=25) contained MDMA
 - The remaining samples contained 4-Chloromethcathinone (n=1), and caffeine (n=1)

Powders/Crystalline (n=47)

- Age range: 20 to 44yrs
 - Median age: 28yrs
 - 74% male / 26% female
- 60 per cent (n=28) contained MDMA
 - 8 contained caffeine, 6 contained 4-Chloromethcathinone, 3 ketamine, 1 ethylone and 1 chloroquine



Potent synthetic opioid

Sample W028505 was submitted as Oxycodone and was found to contain metonitazene

W028505

Date Received: 26 Sep 2022

Postcode: S11 -

Purchase Intent: Oxycodone

Package Label: Not Stated

Sample Colour: Yellow


Sample Form: Tablet

Consumption Method: Not Stated

Self-Reported Effects: Not Stated

Sample Upon Analysis (Major): Metonitazene

Sample Upon Analysis (Minor):



[Click to Enlarge](#)

Metonitazene analgesic effects potency has been indicated as between 30-200 times that of morphine, with respiratory depressant effects estimated at 50 times greater than morphine

World Health Organisation; Critical Review Report:

Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine; 2021 https://cdn.who.int/media/docs/default-source/2021-dha-docs/unedited--advance-copy-44th-ecdd-critical-review-report_metonitazene.pdf?sfvrsn=64eacb39_1&download=true